Olutasidenib and azacitidine for IDH1-mutated AML after venetoclax
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding the targeted therapy olutasidenib to the chemotherapy drug azacitidine can help people with a certain type of AML (one with an IDH1 mutation) who have already had some treatment but still have the disease. The goal is to see if this combination can lead to a longer remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute myeloid leukemia (AML) that has an IDH1 mutation.
- You have already received treatment with a combination of venetoclax and a hypomethylating agent (like azacitidine or decitabine) and achieved a complete or near-complete remission.
- You must be able to swallow pills and have adequate kidney and liver function.
- You are at least 18 years old and willing to use effective birth control during the study and for 90 days after the last dose.
- You have not previously received an IDH1 inhibitor drug (like ivosidenib or olutasidenib) or had a stem cell transplant for non-AML reasons within the last 100 days.
- You are not pregnant or breastfeeding and agree not to donate sperm or conceive a child during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of olutasidenib, venetoclax, and azacitidine for people with newly diagnosed acute myeloid leukemia (AML) that has an IDH1 mutation. It is for patients who are healthy enough for intensive chemotherapy. The goal is to see if this drug combination works better than standard treatment.
This trial tests a drug called olutasidenib, either alone or with other treatments, to see if it can help keep your AML in remission after you've finished your first round of therapy. It's for people whose AML has a specific change in the IDH1 gene.
This trial tests adding a targeted drug (ivosidenib) to standard therapy (azacitidine) with or without another drug (venetoclax) for people with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) or MDS/AML who cannot have strong chemotherapy.
This trial tests a targeted drug, olutasidenib, for people with AML or MDS whose cancer cells have an IDH1-R132 mutation. Depending on your specific diagnosis, you may receive olutasidenib alone or combined with other medicines.
This trial tests a combination of three targeted drugs for people with a specific type of AML that has an IDH1 mutation. The goal is to see if the combination helps control the leukemia and if continuing with just ivosidenib can keep it in remission.
This Phase 2 trial tests different ways of using medicines that target IDH mutations (IDH-targeted treatment) plus venetoclax in people newly diagnosed with IDH-mutated AML. It’s designed for patients who cannot safely receive intensive induction chemotherapy, to see which approach works best and is tolerable.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.